IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Roy Leonard Harris, Iii

USPTO Granted Patents = 17


Average Co-Inventor Count = 14.8

ph-index = 6

Forward Citations = 237(Granted Patents)


Company Filing History:

goldMedal16 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents
silverMedal1 out of 549 
 
Celgene Corporation
 patents

Years Active: 2011-2022

Loading Chart...
Loading Chart...
17 patents (USPTO):
1. 11358952 - Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith (2022-06-14),
2. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),
3. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),
4. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),
5. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2017-10-24),
6. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),
7. 9428509 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-08-30),
8. 9346812 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-05-24),
9. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),
10. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),
11. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),
12. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),
13. 8507492 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway (2013-08-13),
14. 8492381 - Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway (2013-07-23),
15. 8372976 - Methods of treatment comprising the administration of heteroaryl compounds (2013-02-12),

Title: Roy Leonard Harris, III: Innovator in Pharmaceutical Compounds

Introduction

Roy Leonard Harris, III is a prominent inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals, holding a total of 17 patents. His work primarily focuses on innovative compounds and methods that have the potential to impact medical treatments.

Latest Patents

Among his latest patents are the following: "Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith," which details 4-aminoisoindoline-1,3-dione compounds with specific structural properties. Another notable patent is "Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors," which provides heteroaryl compounds and methods for preparing these compounds.

Career Highlights

Throughout his career, Roy has worked with notable companies such as Signal Pharmaceuticals, Inc. and Celgene Corporation. His experience in these organizations has allowed him to develop and refine his innovative ideas in pharmaceutical research.

Collaborations

Roy has collaborated with several professionals in his field, including Jennifer Riggs and Jan Elsner. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Roy Leonard Harris, III is a distinguished inventor whose work in pharmaceutical compounds has led to numerous patents and advancements in medical treatments. His contributions continue to shape the landscape of pharmaceutical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…